Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Whole exome sequencing of low grade serous ovarian carcinoma identifies genomic events associated with clinical outcome.
Thomson JP, Hollis RL, van Baal J, Ilenkovan N, Churchman M, van de Vijver K, Dijk F, Meynert AM, Bartos C, Rye T, Croy I, Diana P, van Gent M, Creedon H, Nirsimloo R, Nussey F, Lok C, Herrington CS, Gourley C. Thomson JP, et al. Among authors: churchman m. Gynecol Oncol. 2023 Jul;174:157-166. doi: 10.1016/j.ygyno.2023.04.011. Epub 2023 May 17. Gynecol Oncol. 2023. PMID: 37207500 Free article.
Distinct histopathological features are associated with molecular subtypes and outcome in low grade serous ovarian carcinoma.
Hollis RL, Thomson JP, van Baal J, Ilenkovan N, Churchman M, van de Vijver K, Dijk F, Meynert AM, Bartos C, Rye T, Croy I, Diana P, van Gent M, Creedon H, Nirsimloo R, Lok C, Gourley C, Herrington CS. Hollis RL, et al. Among authors: churchman m. Sci Rep. 2023 May 11;13(1):7681. doi: 10.1038/s41598-023-34627-5. Sci Rep. 2023. PMID: 37169775 Free PMC article.
High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma.
Hollis RL, Elliott R, Dawson JC, Ilenkovan N, Matthews RM, Stillie LJ, Oswald AJ, Kim H, Llaurado Fernandez M, Churchman M, Porter JM, Roxburgh P, Unciti-Broceta A, Gershenson DM, Herrington CS, Carey MS, Carragher NO, Gourley C. Hollis RL, et al. Among authors: churchman m. Gynecol Oncol. 2024 Jul;186:42-52. doi: 10.1016/j.ygyno.2024.03.029. Epub 2024 Apr 5. Gynecol Oncol. 2024. PMID: 38582027 Free article.
Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses.
Kang EY, Cheasley D, LePage C, Wakefield MJ, da Cunha Torres M, Rowley S, Salazar C, Xing Z, Allan P, Bowtell DDL, Mes-Masson AM, Provencher DM, Rahimi K, Kelemen LE, Fasching PA, Doherty JA, Goodman MT, Goode EL, Deen S, Pharoah PDP, Brenton JD, Sieh W, Mateoiu C, Sundfeldt K, Cook LS, Le ND, Anglesio MS, Gilks CB, Huntsman DG, Kennedy CJ, Traficante N; Australian Ovarian Cancer Study; DeFazio A, Kaufmann S, Churchman M, Gourley C, Stephens AN, Meagher NS, Ramus SJ, Antill YC, Campbell I, Scott CL, Köbel M, Gorringe KL; GAMuT Collaborators. Kang EY, et al. Among authors: churchman m. Mod Pathol. 2021 Jan;34(1):194-206. doi: 10.1038/s41379-020-0618-9. Epub 2020 Jul 28. Mod Pathol. 2021. PMID: 32724153 Free PMC article.
Differential Infiltration of Key Immune T-Cell Populations Across Malignancies Varying by Immunogenic Potential and the Likelihood of Response to Immunotherapy.
Eljilany I, Coleman S, Tan AC, McCarter MD, Carpten J, Colman H, Naqash AR, Puzanov I, Arnold SM, Churchman ML, Spakowicz D, Salhia B, Marin J, Ganesan S, Ratan A, Shriver C, Hwu P, Dalton WS, Weiner GJ, Conejo-Garcia JR, Rodriguez P, Tarhini AA. Eljilany I, et al. Among authors: churchman ml. Cells. 2024 Dec 3;13(23):1993. doi: 10.3390/cells13231993. Cells. 2024. PMID: 39682743 Free PMC article.
Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitors.
Wang X, Li T, Eljilany I, Sukrithan V, Ratan A, McCarter M, Carpten J, Colman H, Ikeguchi AP, Puzanov I, Arnold S, Churchman M, Hwu P, Rodriguez PC, Dalton WS, Weiner GJ, Tarhini AA. Wang X, et al. Among authors: churchman m. medRxiv [Preprint]. 2024 Jul 21:2024.07.19.24310726. doi: 10.1101/2024.07.19.24310726. medRxiv. 2024. PMID: 39072034 Free PMC article. Preprint.
The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors.
Dravillas CE, Coleman SS 4th, Hoyd R, Caryotakis G, Denko L, Chan CHF, Churchman ML, Denko N, Dodd RD, Eljilany I, Hardikar S, Husain M, Ikeguchi AP, Jin N, Ma Q, McCarter MD, Osman AEG, Robinson LA, Singer EA, Tinoco G, Ulrich CM, Zakharia Y, Spakowicz D, Tarhini AA, Tan AC; exORIEN Consortium. Dravillas CE, et al. Among authors: churchman ml. Cancer Res Commun. 2024 Aug 1;4(8):1978-1990. doi: 10.1158/2767-9764.CRC-23-0170. Cancer Res Commun. 2024. PMID: 39015091 Free PMC article.
86 results